Plasma PAFAH/PLA2G7 genetic variability, cardiovascular disease, and clinical trials

Enzymes

Volumn 38, Issue , 2015, Pages 145-155

  Karabina, Sonia ^a   Ninio, Ewa ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

Atherosclerosis; Darapladib; Lp PLA2; PAFAH; PLA2G7

Indexed keywords

EID: 84951320428     PISSN: 18746047     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.enz.2015.09.002     Document Type: Conference Paper

References (51)

1. Tjoelker L.W., Eberhardt C., Unger J., Le Trong H., Zimmerman G.A., McIntyre T.M., Stafforini D.M., Prescott S.M., Gray P.W. Plasma platelet-activating factor acetylhydrolase is a secreted phospholipase A2 with a catalytic triad. J. Biol. Chem. 1995, 43:25481-25487.
2. Min J.H., Jain M.K., Wilder C., Paul L., ApitzCastro R., Aspleaf D.C., Gelb M.H. Membrane-bound plasma platelet activating factor acetylhydrolase acts on substrate in the aqueous phase. Biochemistry 1999, 38:12935-12942.
3. Marathe G.K., Prescott S.M., Zimmerman G.A., McIntyre T.M. Oxidized LDL contains inflammatory PAF-like phospholipids. Trends Cardiovasc. Med. 2001, 11:139-142.
4. Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr. Opin. Lipidol. 2003, 14:421-430.
5. McIntyre T.M., Prescott S.M., Stafforini D.M. The emerging roles of PAF acetylhydrolase. J. Lipid Res. 2009, 50(Suppl.):S255-S259.
6. Steinbrecher U.P., Pritchard P.H. Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase. J. Lipid Res. 1989, 30:305-315.
7. Macphee C.H., Moores K.E., Boyd H.F., Dhanak D., Ife R.J., Leach C.A., Leake D.S., Milliner K.J., Patterson R.A., Suckling K.E., Tew D.G., Hickey D.M.B. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem. J. 1999, 338:479-487.
8. Hakkinen T., Luoma J.S., Hiltunen M.O., Macphee C.H., Milliner K.J., Patel L., Rice S.Q., Tew D.G., Karkola K., YlaHerttuala S. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 1999, 19:2909-2917.
9. Quarck R., De Geest B., Stengel D., Mertens A., Lox M., Theilmeier G., Michiels C., Raes M., Bult H., Collen D., Van Veldhoven P., Ninio E., Holvoet P. Adenovirus-mediated gene transfer of human platelet-activating-factor- acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001, 103:2495-2500.
10. Arakawa H., Qian J.Y., Baatar D., Karasawa K., Asada Y., Sasaguri Y., Miller E.R., Witztum J.L., Ueno H. Local expression of platelet-activating factor-acetylhydrolase reduces accumulation of oxidized lipoproteins and inhibits inflammation, shear stress-induced thrombosis, and neointima formation in balloon-injured carotid arteries in nonhyperlipidemic rabbits. Circulation 2005, 111:3302-3309.
11. Noto H., Hara M., Karasawa K., Iso O.N., Satoh H., Togo M., Hashimoto Y., Yamada Y., Kosaka T., Kawamura M., Kimura S., Tsukamoto K. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress. Arterioscler. Thromb. Vasc. Biol. 2003, 23:829-835.
12. Packard C.J., Demant T., Stewart J.P., Bedford D., Caslake M.J., Schwertfeger G., Bedynek A., Shepherd J., Seidel D. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J. Lipid Res. 2000, 41:305-318.
13. Caslake M.J., Packard C.J. Lipoprotein-associated phospholipase A(2) as a biomarker for coronary disease and stroke. Nat. Clin. Pract. Cardiovasc. Med. 2005, 2:529-535.
14. Rosenson R.S., Stafforini D.M. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J. Lipid Res. 2012, 53:1767-1782.
15. Garza C.A., Montori V.M., McConnell J.P., Somers V.K., Kullo I.J., Lopez-Jimenez F. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin. Proc. 2007, 82:159-165.
16. Sudhir K. Clinical review: lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. J. Clin. Endocrinol. Metab. 2005, 90:3100-3105.
17. Winkler K., Winkelmann B.R., Scharnagl H., Hoffmann M.M., Grawitz A.B., Nauck M., Bohm B.O., Marz W. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation 2005, 111:980-987.
18. Thompson A., Gao P., Orfei L., Watson S., Di Angelantonio E., Kaptoge S., Ballantyne C., Cannon C.P., Criqui M., Cushman M., Hofman A., Packard C., Thompson S.G., Collins R., Danesh J. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010, 375:1536-1544.
19. Blackie J.A., Bloomer J.C., Brown M.J., Cheng H.Y., Hammond B., Hickey D.M., Ife R.J., Leach C.A., Lewis V.A., Macphee C.H., Milliner K.J., Moores K.E., Pinto I.L., Smith S.A., Stansfield I.G., Stanway S.J., Taylor M.A., Theobald C.J. The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2. Bioorg. Med. Chem. Lett. 2003, 13:1067-1070.
20. Rosenson R.S., Hurt-Camejo E. Phospholipase A2 enzymes and the risk of atherosclerosis. Eur. Heart J. 2012, 33:2899-2909.
21. Wilensky R.L., Shi Y., Mohler E.R., Hamamdzic D., Burgert M.E., Li J., Postle A., Fenning R.S., Bollinger J.G., Hoffman B.E., Pelchovitz D.J., Yang J., Mirabile R.C., Webb C.L., Zhang L., Zhang P., Gelb M.H., Walker M.C., Zalewski A., Macphee C.H. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat. Med. 2008, 14:1059-1066.
22. Gerrity R.G., Natarajan R., Nadler J.L., Kimsey T. Diabetes-induced accelerated atherosclerosis in swine. Diabetes 2001, 50:1654-1665.
23. Mohler E.R., Sarov-Blat L., Shi Y., Hamamdzic D., Zalewski A., Macphee C., Llano R., Pelchovitz D., Mainigi S.K., Osman H., Hallman T., Steplewski K., Gertz Z., Lu M.M., Wilensky R.L. Site-specific atherogenic gene expression correlates with subsequent variable lesion development in coronary and peripheral vasculature. Arterioscler. Thromb. Vasc. Biol. 2008, 28:850-855.
24. Thim T., Hagensen M.K., Wallace-Bradley D., Granada J.F., Kaluza G.L., Drouet L., Paaske W.P., Botker H.E., Falk E. Unreliable assessment of necrotic core by virtual histology intravascular ultrasound in porcine coronary artery disease. Circ. Cardiovasc. Imaging 2010, 3:384-391.
25. De Keyzer D., Karabina S.A., Wei W., Geeraert B., Stengel D., Marsillach J., Camps J., Holvoet P., Ninio E. Increased PAFAH and oxidized lipids are associated with inflammation and atherosclerosis in hypercholesterolemic pigs. Arterioscler. Thromb. Vasc. Biol. 2009, 29:2041-2046.
26. Karabina S.A., Gora S., Atout R., Ninio E. Extracellular phospholipases in atherosclerosis. Biochimie 2010, 92:594-600.
27. Serruys P.W., Garcia-Garcia H.M., Buszman P., Erne P., Verheye S., Aschermann M., Duckers H., Bleie O., Dudek D., Botker H.E., von Birgelen C., D'Amico D., Hutchinson T., Zambanini A., Mastik F., van Es G.A., van der Steen A.F., Vince D.G., Ganz P., Hamm C.W., Wijns W., Zalewski A. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008, 118:1172-1182.
28. White H.D., Held C., Stewart R., Tarka E., Brown R., Davies R.Y., Budaj A., Harrington R.A., Steg P.G., Ardissino D., Armstrong P.W., Avezum A., Aylward P.E., Bryce A., Chen H., Chen M.F., Corbalan R., Dalby A.J., Danchin N., De Winter R.J., Denchev S., Diaz R., Elisaf M., Flather M.D., Goudev A.R., Granger C.B., Grinfeld L., Hochman J.S., Husted S., Kim H.S., Koenig W., Linhart A., Lonn E., Lopez-Sendon J., Manolis A.J., Mohler E.R., Nicolau J.C., Pais P., Parkhomenko A., Pedersen T.R., Pella D., Ramos-Corrales M.A., Ruda M., Sereg M., Siddique S., Sinnaeve P., Smith P., Sritara P., Swart H.P., Sy R.G., Teramoto T., Tse H.F., Watson D., Weaver W.D., Weiss R., Viigimaa M., Vinereanu D., Zhu J., Cannon C.P., Wallentin L. Darapladib for preventing ischemic events in stable coronary heart disease. N. Engl. J. Med. 2014, 370:1702-1711.
29. O'Donoghue M.L., Braunwald E., White H.D., Lukas M.A., Tarka E., Steg P.G., Hochman J.S., Bode C., Maggioni A.P., Im K., Shannon J.B., Davies R.Y., Murphy S.A., Crugnale S.E., Wiviott S.D., Bonaca M.P., Watson D.F., Weaver W.D., Serruys P.W., Cannon C.P., Steen D.L. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 2014, 312:1006-1015.
30. Johnson J.L., Shi Y., Snipes R., Janmohamed S., Rolfe T.E., Davis B., Postle A., Macphee C.H. Effect of darapladib treatment on endarterectomy carotid plaque lipoprotein-associated phospholipase A2 activity: a randomized, controlled trial. PLoS One 2014, 9:e89034.
31. Marathe G.K., Pandit C., Lakshmikanth C.L., Chaithra V.H., Jacob S.P., D'Souza C.J. To hydrolyze or not to hydrolyze: the dilemma of platelet-activating factor acetylhydrolase. J. Lipid Res. 2014, 55:1847-1854.
32. Mullard A. GSK's darapladib failures dim hopes for anti-inflammatory heart drugs. Nat. Rev. Drug Discov. 2014, 13:481-482.
33. O'Donoghue M.L. Acute coronary syndromes: targeting inflammation-what has the VISTA-16 trial taught us?. Nat. Rev. Cardiol. 2014, 11:130-132.
34. Miwa M., Miyake T., Yamanaka T., Sugatani J., Suzuki Y., Sakata S., Araki Y., Matsumoto M. Characterization of serum platelet-activating factor (PAF) acetylhydrolase: correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J. Clin. Invest. 1983, 82:1983-1991.
35. Stafforini D.M., Numao T., Tsodikov A., Vaitkus D., Fukuda T., Watanabe N., Fueki N., McIntyre T.M., Zimmerman G.A., Makino S., Prescott S.M. Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma. J. Clin. Invest. 1999, 103:989-997.
36. Yamada Y., Ichihara S., Fujimura T., Yokota M. Identification of the G994/T missense mutation in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism 1998, 47:177-181.
37. Yamada Y., Yoshida H., Ichihara S., Imaizumi T., Satoh K., Yokota M. Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age and atherosclerosis in a Japanese population. Atherosclerosis 2000, 150:209-216.
38. Unno N., Nakamura T., Kaneko H., Uchiyama T., Yamamoto N., Sugatani J., Miwa M., Nakamura S. Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in Japan. J. Vasc. Surg. 2000, 32:263-267.
39. Jang Y., Kim O.Y., Koh S.J., Chae J.S., Ko Y.G., Kim J.Y., Cho H., Jeong T.S., Lee W.S., Ordovas J.M., Lee J.H. The Val279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men. J. Clin. Endocrinol. Metab. 2006, 91:3521-3527.
40. Jang Y., Waterworth D., Lee J.E., Song K., Kim S., Kim H.S., Park K.W., Cho H.J., Oh I.Y., Park J.E., Lee B.S., Ku H.J., Shin D.J., Lee J.H., Jee S.H., Han B.G., Jang H.Y., Cho E.Y., Vallance P., Whittaker J., Cardon L., Mooser V. Carriage of the V279F null allele within the gene encoding Lp-PLA(2) is protective from coronary artery disease in South Korean males. PLoS One 2011, 6:e18208.
41. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232:34-47.
42. Brooks-Wilson A., Marcil M., Clee S.M., Zhang L.H., Roomp K., van Dam M., Yu L., Brewer C., Collins J.A., Molhuizen H.O., Loubser O., Ouelette B.F., Fichter K., Ashbourne-Excoffon K.J., Sensen C.W., Scherer S., Mott S., Denis M., Martindale D., Frohlich J., Morgan K., Koop B., Pimstone S., Kastelein J.J., Genest J., Hayden M.R. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 1999, 22:336-345.
43. Abifadel M., Varret M., Rabes J.P., Allard D., Ouguerram K., Devillers M., Cruaud C., Benjannet S., Wickham L., Erlich D., Derre A., Villeger L., Farnier M., Beucler I., Bruckert E., Chambaz J., Chanu B., Lecerf J.M., Luc G., Moulin P., Weissenbach J., Prat A., Krempf M., Junien C., Seidah N.G., Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 2003, 34:154-156.
44. Guerra R., Zhao B., Mooser V., Stafforini D., Johnston J.M., Cohen J.C. Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins. J. Lipid Res. 1997, 38:2281-2288.
45. Kruse S., Mao X.-Q., Heinzman A., Blattmann S., Roberts M.H., Braun S., Gao P.-S., Forster J., Kuehr J., Hopkins J.M., Shirakawa T., Deichman K.A. The Ile198Thr and Ala379Val variants of plasmatic Paf-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am. J. Hum. Genet. 2000, 66:1522-1530.
46. Ninio E., Tregouet D., Carrier J.L., Stengel D., Bickel C., Perret C., Rupprecht H.J., Cambien F., Blankenberg S., Tiret L. Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Hum. Mol. Genet. 2004, 13:1341-1351.
47. Abuzeid A.M., Hawe E., Humphries S.E., Talmud P.J. Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis 2003, 168:283-288.
48. Sutton B.S., Crosslin D.R., Shah S.H., Nelson S.C., Bassil A., Hale A.B., Haynes C., Goldschmidt-Clermont P.J., Vance J.M., Seo D., Kraus W.E., Gregory S.G., Hauser E.R. Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets. Hum. Mol. Genet. 2008, 17:1318-1328.
49. Casas J.P., Ninio E., Panayiotou A., Palmen J., Cooper J.A., Ricketts S.L., Sofat R., Nicolaides A.N., Corsetti J.P., Fowkes F.G., Tzoulaki I., Kumari M., Brunner E.J., Kivimaki M., Marmot M.G., Hoffmann M.M., Winkler K., Marz W., Ye S., Stirnadel H.A., Boekholdt S.M., Khaw K.T., Humphries S.E., Sandhu M.S., Hingorani A.D., Talmud P.J. PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. Circulation 2010, 121:2284-2293.
50. Schnabel R., Dupuis J., Larson M.G., Lunetta K.L., Robins S.J., Zhu Y., Rong J., Yin X., Stirnadel H.A., Nelson J.J., Wilson P.W., Keaney J.F., Vasan R.S., Benjamin E.J. Clinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study. Atherosclerosis 2009, 204:601-607.
51. Dentan C., Lesnik P., Chapman M.J., Ninio E. PAF-acether-degrading acetylhydrolase in plasma LDL is inactivated by copper- and cell-mediated oxidation. Arterioscler. Thromb. 1994, 14:353-360.